Tildrakizumab MK3222, an Anti IL23p19 Monoclonal Antibody, Improves Psoriasis in a Phase 2b Randomized Placebo Controlled Trial

http://www.medworm.com/index.php?rid=113559544&cid=c_64_12_f&fid=31732&url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fbjd.13932

Comments are closed.